By Professor Caroline Ford

Journal articles

Cortesi M; Liu D; Yee C; Marsh DJ; Ford CE, 2024, 'Author Correction: A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models (Scientific Reports, (2023), 13, 1, (15769), 10.1038/s41598-023-42486-3)', Scientific Reports, 14, http://dx.doi.org/10.1038/s41598-023-50403-x

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford CE, 2024, 'Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer', Molecular Oncology, 18, pp. 2668 - 2683, http://dx.doi.org/10.1002/1878-0261.13710

Madani DD; Satgunaseelan DL; El-Hayek MJ; Shivalingam PB; Ford PC, 2024, 'ROR1 MRNA EXPRESSION IN GLIOMA - A NOVEL PROGNOSTIC BIOMARKER', Neuro-Oncology, 26, pp. vii4 - vii5, http://dx.doi.org/10.1093/neuonc/noae158.016

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford C, 2024, 'Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.', Journal of Clinical Oncology, 42, pp. 5547 - 5547, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5547

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE, 2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43, http://dx.doi.org/10.1016/j.tranon.2024.101914

Liu D; Powell E; Wan KM; Athavale R; Loo C; Ford CE, 2024, 'Abstract B014: Patient-derived organoid models for drug screening in molecular subtypes of endometrial cancer', Clinical Cancer Research, 30, pp. B014 - B014, http://dx.doi.org/10.1158/1557-3265.endo24-b014

Fisher T; Powell E; Yuwono NL; Ford CE; Warton K, 2024, 'Circulating cell-free DNA is elevated in postmenopausal compared with pre- and perimenopausal women', Menopause, 31, pp. 171 - 175, http://dx.doi.org/10.1097/GME.0000000000002313

Cortesi M; Liu D; Powell E; Barlow E; Warton K; Ford CE, 2024, 'Accurate Identification of Cancer Cells in Complex Pre-Clinical Models Using a Deep-Learning Neural Network: A Transfection-Free Approach', Advanced Biology, http://dx.doi.org/10.1002/adbi.202400034

Cortesi M; Warton K; Ford CE, 2024, 'Beyond 2D cell cultures: how 3D models are changing the in vitro study of ovarian cancer and how to make the most of them', PeerJ, 12, http://dx.doi.org/10.7717/peerj.17603

Cortesi M; Liu D; Yee C; Marsh DJ; Ford CE, 2023, 'A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-42486-3

Wong-Brown MWY; Johnson Z; Salem S; Matthews BG; Ford CE; Marsh DJ; Bowden NA, 2023, 'Abstract C041: Drug repurposing to target TGF-β in chemoresistant high-grade serous ovarian cancer', Molecular Cancer Therapeutics, 22, pp. C041 - C041, http://dx.doi.org/10.1158/1535-7163.targ-23-c041

Phan Z; Ford CE; Caldon CE, 2023, 'DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review', Pharmacological Research, 196, http://dx.doi.org/10.1016/j.phrs.2023.106927

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.', Journal of Clinical Oncology, 41, pp. 5561 - 5561, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5561

Weir A; Kang EY; Meagher NS; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Gentry-Maharaj A; Ryan A; Singh N; Widschwendter M; Alsop J; Anglesio MS; Beckmann MW; Berger J; Bisinotto C; Boros J; Brand AH; Brenton JD; Brooks-Wilson A; Carney ME; Cunningham JM; Cushing-Haugen KL; Cybulski C; Elishaev E; Erber R; Fereday S; Fischer A; Paz-Ares L; Gayarre J; Gilks BC; Grube M; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Heublein S; Huang Y; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kommoss FKF; Koziak JM; Kraemer B; Le ND; Lesnock J; Lester J; Lubiński J; Menkiszak J; Ney B; Olawaiye A; Orsulic S; Osorio A; Robles-Díaz L; Ruebner M; Shah M; Sharma R; Shvetsov YB; Steed H; Talhouk A; Taylor SE; Traficante N; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DDL; Candido dos Reis FJ; Cook LS; DeFazio A; DeFazio A; Traficante N; Harnett P; Doherty JA; Fasching PA; García MJ; Goode EL; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kommoss S; Modugno F; Schildkraut JM; Sinn HP; Staebler A; Kelemen LE; Ford CE; Menon U; Pharoah PDP; Köbel M; Ramus SJ, 2023, 'Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study', British Journal of Cancer, 128, pp. 137 - 147, http://dx.doi.org/10.1038/s41416-022-02014-y

Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2022, 'Author Correction: ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target (Scientific Reports, (2020), 10, 1, (13906), 10.1038/s41598-020-70924-z)', Scientific Reports, 12, http://dx.doi.org/10.1038/s41598-022-15043-7

Henry CE; Llamosas E; Djordjevic A; Hacker NF; Ford CE, 2022, 'Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer (Oncogenesis, (2016), 5, 5, (e226), 10.1038/oncsis.2016.32)', Oncogenesis, 11, http://dx.doi.org/10.1038/s41389-022-00408-4

Madani D; John M; Satgunaseelan L; Shivalingam B; Ford C, 2022, 'BIOM-11. ROR1 MRNA EXPRESSION IN GLIOMA - A NOVEL PROGNOSTIC BIOMARKER', Neuro-Oncology, 24, pp. vii6 - vii6, http://dx.doi.org/10.1093/neuonc/noac209.021

Yuwono NL; Alonso A; Abbott J; Houshdaran S; Henry CE; Rodgers R; Ford CE; Warton K, 2022, 'Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis', Human Reproduction, 37, pp. 2560 - 2569, http://dx.doi.org/10.1093/humrep/deac198

Werner B; Warton K; Ford CE, 2022, 'Endogenous cell-free DNA in fetal bovine serum introduces artifacts to in vitro cell-free DNA models', BioTechniques, 73, pp. 219 - 226, http://dx.doi.org/10.2144/btn-2022-0040

John M; Ford CE, 2022, 'Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1', Biomedicines, 10, pp. 2559, http://dx.doi.org/10.3390/biomedicines10102559

Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ, 2022, 'Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival', Cancers, 14, http://dx.doi.org/10.3390/cancers14194621

Fisher T; Ford CE; Warton K, 2022, 'Recovery Efficiency of Cell-Free DNA After Bisulfite Conversion', Clinical Chemistry, 68, pp. 1219 - 1220, http://dx.doi.org/10.1093/clinchem/hvac107

Yuwono NL; Boyd MAA; Henry CE; Werner B; Ford CE; Warton K, 2022, 'Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form', Clinical Chemistry and Laboratory Medicine, 60, pp. 1287 - 1298, http://dx.doi.org/10.1515/cclm-2021-1152

Liu D; Kaufmann GF; Breitmeyer JB; Dickson KA; Marsh DJ; Ford CE, 2022, 'The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells', Pharmaceutics, 14, http://dx.doi.org/10.3390/pharmaceutics14040837

Alonso A; Yuwono NL; Houshdaran S; Abbott J; Rodgers R; Ford CE; Warton K, 2022, 'Comparison of total and endometrial circulating cell-free DNA in women with and without endometriosis', Reproductive BioMedicine Online, 44, pp. 495 - 503, http://dx.doi.org/10.1016/j.rbmo.2021.11.006

Werner B; Warton K; Ford CE, 2022, 'Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology', Cancers, 14, http://dx.doi.org/10.3390/cancers14051309

Liu D; Sharbeen G; Phillips P; Johns AL; Gill AJ; Chantrill LA; Timpson P; Chou A; Pajic M; Dwarte T; Herrmann D; Vennin C; Cox TR; Pereira B; Ritchie S; Reed DA; Chambers CR; Metcalf X; Nobis M; Waddell N; Pearson JV; Patch AM; Nones K; Newell F; Mukhopadhyay P; Addala V; Kazakoff S; Holmes O; Leonard C; Wood S; Grimmond SM; Hofmann O; Samra JS; Pavlakis N; Arena J; High HA; Asghari R; Merrett ND; Das A; Cosman PH; Ismail K; Stoita A; Williams D; Spigellman A; Lam VW; McLeod D; Kirk J; Kench JG; Grimison P; Sandroussi C; Goodwin A; Mead RS; Tucker K; Andrews L; Texler M; Forrest C; Ballal M; Fletcher D; Beilin M; Feeney K; Epari K; Mukhedkar S; Zeps N; Nguyen NQ; Ruszkiewicz AR; Worthley C; Chen J; Brooke-Smith ME; Papangelis V; Clouston AD; Barbour AP; O’Rourke TJ; Fawcett JW; Slater K; Hatzifotis M; Hodgkinson P; Nikfarjam M; Eshleman JR; Hruban RH; Wolfgang CL; Scarpa A; Lawlor RT; Corbo V; Bassi C; Biankin AV; Jamieson NB; Chang DK; Dreyer SB; Ford CE, 2021, 'ROR1 and ROR2 expression in pancreatic cancer', BMC Cancer, 21, http://dx.doi.org/10.1186/s12885-021-08952-9

Joshi N; Liu D; Dickson KA; Marsh DJ; Ford CE; Stenzel MH, 2021, 'An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles', Journal of Materials Chemistry B, 9, pp. 9123 - 9135, http://dx.doi.org/10.1039/d1tb01837j

Yuwono NL; Warton K; Ford CE, 2021, 'The influence of biological and lifestyle factors on circulating cell-free dna in blood plasma', eLife, 10, http://dx.doi.org/10.7554/eLife.69679

Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727, http://dx.doi.org/10.1016/j.ygyno.2021.06.028

Hagstrom AD; Yuwono N; Warton K; Ford CE, 2021, 'Sex Bias in Cohorts Included in Sports Medicine Research', Sports Medicine, 51, pp. 1799 - 1804, http://dx.doi.org/10.1007/s40279-020-01405-6

Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y

Yuwono NL; Henry CE; Ford CE; Warton K, 2021, 'Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation', PLoS ONE, 16, http://dx.doi.org/10.1371/journal.pone.0250561

Liu D; Enriquez L; Ford CE, 2021, 'Ror2 is epigenetically regulated in endometrial cancer', Cancers, 13, pp. 1 - 16, http://dx.doi.org/10.3390/cancers13030383

Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2020, 'ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target', Scientific Reports, 10, http://dx.doi.org/10.1038/s41598-020-70924-z

Ford CE; Werner B; Hacker NF; Warton K, 2020, 'The untapped potential of ascites in ovarian cancer research and treatment', British Journal of Cancer, 123, pp. 9 - 16, http://dx.doi.org/10.1038/s41416-020-0875-x

Warton K; Xu Y; Ford CE, 2020, 'Target sequence heterogeneity causes the 'hook effect' in fluorescent dye-based quantitative PCR', BioTechniques, 69, pp. 81 - 84, http://dx.doi.org/10.2144/BTN-2020-0016

Werner B; Yuwono NL; Henry C; Gunther K; Rapkins RW; Ford CE; Warton K, 2019, 'Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight', PLoS ONE, 14, http://dx.doi.org/10.1371/journal.pone.0224338

Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH, 2019, 'A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles', Biomaterials Science, 7, pp. 1652 - 1660, http://dx.doi.org/10.1039/c8bm01326h

Huynh KT; Van Zuylen WJ; Ford CE; Rawlinson WD, 2019, 'Selective modulation of wnt-binding receptor tyrosine kinase ROR2 expression by human cytomegalovirus regulates trophoblast migration', Journal of General Virology, 100, pp. 99 - 104, http://dx.doi.org/10.1099/jgv.0.001179

Coopes A; Henry CE; Llamosas E; Ford CE, 2018, 'An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target', Endocrine-Related Cancer, 25, pp. R647 - R662, http://dx.doi.org/10.1530/ERC-18-0112

Cortesi M; Llamosas E; Henry CE; Kumaran RYA; Ng B; Youkhana J; Ford CE, 2018, 'I-AbACUS: A Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell Assays', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-22091-5

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, 148, pp. 576 - 584, http://dx.doi.org/10.1016/j.ygyno.2018.01.025

Warton K; Yuwono NL; Cowley MJ; McCabe MJ; So A; Ford CE, 2017, 'Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma', Molecular Diagnosis and Therapy, 21, pp. 563 - 570, http://dx.doi.org/10.1007/s40291-017-0284-x

Henry CE; Emmanuel C; Lambie N; Loo C; Kan B; Kennedy CJ; de Fazio A; Hacker NF; Ford CE, 2017, 'Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer', Translational Oncology, 10, pp. 346 - 356, http://dx.doi.org/10.1016/j.tranon.2017.01.014

Henry C; Hacker N; Ford C, 2017, 'Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis', Oncotarget, 8, pp. 112727 - 112738, http://dx.doi.org/10.18632/oncotarget.22559

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv : an international journal of pathology, 470, pp. 99 - 108, http://dx.doi.org/10.1007/s00428-016-2019-5

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, 469, pp. 717, http://dx.doi.org/10.1007/s00428-016-2036-4

Hesson LB; Ng B; Zarzour P; Srivastava S; Kwok CT; Packham D; Nunez AC; Beck D; Ryan R; Dower A; Ford CE; Pimanda JE; Sloane MA; Hawkins NJ; Bourke MJ; Wong JWH; Ward RL, 2016, 'Integrated genetic, epigenetic, and transcriptional profiling identifies molecular pathways in the development of laterally spreading tumors', Molecular Cancer Research, 14, pp. 1217 - 1228, http://dx.doi.org/10.1158/1541-7786.MCR-16-0175

Ma S; srivastava S; llamosas E; hawkins N; hesson L; ward R; Ford C, 2016, 'ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.', BMC Cancer, 16, pp. 508, http://dx.doi.org/10.1186/s12885-016-2576-7

Back to profile page